{"ticker": {"uuid": "c20d24dc-8171-4b41-b7e5-d6f8b19bd5eb", "symbol": "IMDX", "name": "Insight Molecular Diagnostics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNUUpkR2h0T0JuSHFUUDc0M0doWDd6bmpVOFFGMk5jaGlNY2hGcGo1VDVvbTRueG4xUkpWUE1LREhqSHg0dzRhZGktZExmeHgzdUFnUUlwdU9waVRkUEs3QU1EQW9jcUdLNHBNZzBnUVN6cFotb3FMeUFaSEs5VmExeWZFLWtpbVh1MTZIdGhNdWlfenhhbXBwNEllWlhkZ05OWlRLVUVQR1B5bnZLdmI2aTZlUXl4Q2ZfczRnVzZ1TllXeUlrN0ZJbEZHaw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T05:17:08+00:00", "published_display": "21 Jul 2026 05:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen stock trades steady as investors weigh recent earnings and diagnostics demand", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOY2lWQW5SZGVnT0ZmTkxpMTJ1YUx2ai1jYWFiWkRrZzBXZ056bzBnQzhjczF1OXp4YjM0cGJjNGxweDJsXzA0OFpBbGRHd3hHeU1NdlRUcTUycWI3WlVpZ3JZMk1yeGlFTnpwQnRZSHR3MGNKQ25yRkF0Zy1CYS0zRmJrbnM4UHJKMHREWV9QZU04Slh1eHItME5vRW1EaTctN3d4bHJiYjFyOENwWTY1QXlZT292cnV3cmdiMnJUM1lSdw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T11:16:28+00:00", "published_display": "20 Jul 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEXX Laboratories stock stays anchored to its diagnostics growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQTGtXazQ2emZha2llSjlaYldkV01VdWhuc3htd1BRQ3B2OVNQTzJxTEktT2hKdFdMNDhxRWVlV0ZkY0dmRHhHOFh0X0xXOU9WcGx5UEFRS2JGLUtHTWluOXVWSEplLUpTOC1zQzlNWDNpcEVUdnA4ZDFlbU1UTC03cHVQdDg2cHlteFE4RmxKc3A2MHhldzNZVHF6ZlJxOTUtNklORkYtRURkT1dPTTM3UHdzMXhuSTV5aGIyTW81WmpUZw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T10:50:44+00:00", "published_display": "20 Jul 2026 10:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its enterprise value to revenue forward. The content, sourced from TradingView, indicates a market closed status with no trades and highlights financial dat", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T06:40:16", "published_display": "20 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen stock trades steady as diagnostics demand supports earnings and cash flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQeEE2NXcxNFlzM2VhVkZjX3lMajV3QzNVd1V2d3dXMllRUzVNa2RHbzVhcEZueEpnZFpyYXNKOU9ZZzdtOXdzMVZoRUV0bEd1MVFJYkJKSzAzSjdaajdVUi1TR1RfZmJrNDIydWI2R2dlRU1jdmU5NmV6dDNwZ3pWdG1BRTNHZjVabTdtUzNpckNCX2V5VVIteVkwVzZfMmJNVlNTZy1Tb2t2M0dEZDM3TmoxaGlkZ2lvX1RQWWZZYk9PVjJMNXFzSQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-19T01:57:24+00:00", "published_display": "19 Jul 2026 01:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medicare expands coverage for transplant monitoring test, boosting Insight Molecular Diagnostics' GraftAssure adoption.", "summary": "Medicare has expanded its coverage for donor-derived cell-free DNA (dd-cfDNA) testing, which will increase patient access and testing frequency for kidney and heart transplant recipients. This policy change will benefit Insight Molecular Diagnostics (iMDx) and its GraftAssure tra", "url": "https://pluang.com/en/news-feed/keputusan-medicare-mendukung-adopsi-komersial-portofolio-graftassure-imdx", "source_name": "Pluang", "published_at": "2026-07-16T20:11:30", "published_display": "16 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing", "summary": "Insight Molecular Diagnostics Inc. (iMDx) announced that Medicare has expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care, a move expected to boost the commercial adoption of its GraftAssure\u2122 assays. The new MolDX policy clarifies reimbursement", "url": "https://www.quiverquant.com/news/iMDx+Highlights+Expanded+Medicare+Coverage+for+Donor-Derived+Cell-Free+DNA+Transplant+Testing", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T19:30:00", "published_display": "16 Jul 2026 19:30", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio", "summary": "Insight Molecular Diagnostics Inc. (iMDx) has announced a favorable new Medicare policy that significantly expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. This policy clarifies reimbursement guidelines, increases testing frequencies for tra", "url": "https://www.globenewswire.com/fr/news-release/2026/07/16/3328769/0/en/favorable-medicare-coverage-decision-supports-commercial-adoption-of-imdx-graftassure-assay-portfolio.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T15:22:00", "published_display": "16 Jul 2026 15:22", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its \"Price to book forward\" metric. It appears to be an entry from a financial data platform, giving a snapshot of the company's valuation for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T10:10:28", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen stock holds steady as diagnostics demand supports long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQYXRxTGlQaFZybjJ5a2J0WHl5bXp5QTRPMS1vTG5XVUoyU3Z4ZlRiSnUtRTQ2TWF4dG9FSzkwYmRYcnhDZUFqXzVuSTdFVEg1eVU0TXBNS2k0V2xEdm9MR3lzNTlCMzN3UEpMNmppZTlfbEZRWGloRm84VjllY0dtTUNMM3pCZFdyVUlPaS1saXdOOU1OVzVDa29zRURQZXlsRVZ6M3pITWVVSmVyQXZpSXIwWGxyaWxQZ1VNRTgwRGo4RndMZEE2MERVZlQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-13T06:08:44+00:00", "published_display": "13 Jul 2026 06:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "The article provides a financial statistic, specifically the Enterprise Value to EBIT (Earnings Before Interest and Taxes) forward for Insight Molecular Diagnostics Inc. (NASDAQ:IMDX). It appears to be a stub or a data point from a financial platform like TradingView, indicating ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T07:39:55", "published_display": "12 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roche stock holds steady as pharma giant leans on diagnostics and oncology strength", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPa0hsdjNPUWxBTFVtcXYyOUpSbnB0WnpoR1k5c1EyaFVPOXJmR0NROGpoazIwMC1FWFFiYmh4VGl5ZkZHbEFtNXNBalBIbTY5Q29aSXdNTkpiNEU4ZDdIZHJ2SjNoYjRqaHBLdUNSYTBieUhEdHBzc1V0UFQ3QkxPZ0s0d2pSWWhid3pOQW5uMUVHRmRpQmpCa0FkY2hrVHM4c2ViTFRWOWpLVkY2NWpBM0FuMkFDZWlUaG5ncWl4ckxNeENDMjhHWVpUSG8xUQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-11T08:31:21+00:00", "published_display": "11 Jul 2026 08:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "This article provides a specific financial metric, \"Price to sales forward,\" for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX). The content is primarily a listing from TradingView, highlighting the company's stock information, along with various platform features and disclaim", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T12:40:45", "published_display": "10 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Insight Molecular Diagnostics Inc For: 6 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Molecular Diagnostics Inc. on July 6th, 2026. The filing indicates insider transaction activity for the company, which is trading down 12.59% (IMDX). The article provides no further details on the nature of the Form 4", "url": "https://ng.investing.com/news/stock-market-news/form-4-insight-molecular-diagnostics-inc-for-6-july-93CH-2587994", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T04:39:14", "published_display": "07 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Lou Silverman has IMDX shares withheld for taxes (NASDAQ: IMDX)", "summary": "Insight Molecular Diagnostics Inc. director Lou Silverman reported that 7,700 shares of common stock, valued at $5.69 per share, were withheld to cover tax obligations arising from the vesting of 35,000 restricted stock units. This was not a market sale, but a routine tax-related", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-0d03de98f339.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:06", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular (IMDX) director uses 12,100 shares to cover RSU tax withholding", "summary": "Insight Molecular Diagnostics Inc. director Arno Andrew reported that 12,100 shares of Common Stock, valued at $5.69 per share, were withheld by the company to cover tax obligations related to the vesting of 55,000 restricted stock units. Critically, Andrew did not sell any share", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-f85382365a76.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:06", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics (Nasdaq: IMDX) details director RSU tax withholding", "summary": "Insight Molecular Diagnostics director Andrew J. Last reported a tax-withholding transaction related to vested restricted stock units (RSUs). For tax obligations on 35,000 RSUs, 7,700 shares of common stock were withheld at $5.69 per share. This was not an open-market sale, and L", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-410314e347ba.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:06", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quest Diagnostics (DGX) Stock Analysis: Revenue Growth and Dividend Yield Capture Investor Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNYkVVSF9CRDFhU0s1LVZ0V0diSmdaUjB4bGd0Y0V1d2tlVVdLY2FCNjdmODBvQjBCaDRoazNuQ2RQTmtBcUFTeHdXckpzNWwwbnNpS1F1YUdqSld1Y3Rkay1SaHNPdDh5RHpQV1pyVHBsMHh1ZG5iOUo5eUE4QnE4TTFrQ1JOaXQ5RmduVVF4d3dtZWE0WExvRy1JdU95RmZocjMwUElOZUUzcHI2RlRVNmZEYklLR1o4a2lONDFBRDlucUNXQk1fQ3JuSnRxS2k5QkJOR3psNlFFWUhOUGszZ2Zn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:16:18+00:00", "published_display": "06 Jul 2026 09:16", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Insight Molecular Diagnostics Inc. (IMDX)", "summary": "This article examines the hypothetical return on a $1,000 investment in Insight Molecular Diagnostics Inc. (IMDX). It shows that an investment made one year ago would now be worth $1,694, representing a 69.4% total return. The piece also provides a detailed overview of the compan", "url": "https://www.stocktitan.net/tools/stock-return-calculator/IMDX", "source_name": "Stock Titan", "published_at": "2026-07-06T04:39:14", "published_display": "06 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX - Insight Molecular Diagnostics Inc Website Traffic and Mobile Apps Usage", "summary": "This article provides a detailed financial overview of Insight Molecular Diagnostics Inc. (IMDX), including stock performance, key financial metrics, recent news, and insider trading activity. It highlights the company's focus on diagnostic tests for cancer and transplant monitor", "url": "https://finviz.com/stock?t=IMDX&ty=tr", "source_name": "Finviz", "published_at": "2026-07-04T11:09:14", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics (Nasdaq:IMDX) - Stock Analysis", "summary": "Insight Molecular Diagnostics (IMDX) operates as a precision diagnostics company with a market cap of US$183.7 million. While the company faces risks such as a highly volatile share price, negative shareholder equity, unprofitability, and minimal revenue, it anticipates significa", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics", "source_name": "Simply Wall Street", "published_at": "2026-07-01T14:39:44", "published_display": "01 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper", "summary": "Insight Molecular Diagnostics Inc. (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. Dr. Schuetz is a co-inventor of the dd-cfDNA testing technology used in iMDx\u2019s GraftAssure assays and is recognized as a top", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318899/0/en/imdx-chief-science-officer-ekkehard-schuetz-publishes-200th-research-paper.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:09:33", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx science chief hits 200 papers as transplant test work builds", "summary": "Insight Molecular Diagnostics (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. Dr. Schuetz co-invented the dd-cfDNA technology central to iMDx's GraftAssure assays, which are designed for transplant rejection", "url": "https://www.stocktitan.net/news/IMDX/im-dx-chief-science-officer-ekkehard-schuetz-publishes-200th-kd8kokxwmwnt.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:09:33", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc. Actuals & Estimates (NASDAQ:IMDX)", "summary": "This article provides an overview of Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), detailing its current stock price, historical performance, and analyst forecasts. It includes key financial data like market capitalization, earnings per share, and revenue, along with employe", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T13:13:12", "published_display": "27 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX)", "summary": "This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It covers stock performance, earnings reports, revenue, net income, and EBITDA, along with freque", "url": "https://www.tradingview.com/symbols/BOATS-IMDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:39:18", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen N.V. updates earnings calendar, shares tracked against diagnostics peers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOUTNqbEpUTW4xd3RUTE5nMEt0ZEJFT25xZVBoYjRYYk56b18xdkwyWFJncVR1cjMwa25pbUhudWk2Ukk5RlBqLU1fRXo5YmZXNlZQMG5ubnExM1o4YXZpSDE3enY4T0MtLTVIS1dnYUlVWTZMNW5HVkFKNVFFbFZRVnQ3Z0ZkNnJmN0NMRHVRZXJtQkw2b1RUazZSZW1yaTVCM0VVYU9RM1o3YWF4MHlZM2ppSWZnekVxUEN4Y01GaWRiUXVTMHE0bXRB?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T05:11:57+00:00", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing", "summary": "Insight Molecular Diagnostics (IMDX) is poised for a significant repricing due to its GraftAssure transplant monitoring test. Recent Clinical Chemistry and American Journal of Transplantation articles highlight its high concordance, diagnostic performance, and potential for earli", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics/stf1tyro-rising-global-organ-transplants-will-drive-diagnostic-testing-expansion-55ap/updates/20-analysts-have-adjusted-their-price-target-for-insight-molecu", "source_name": "Simply Wall Street", "published_at": "2026-06-25T02:09:49", "published_display": "25 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imdx-american-society-transplant-surgeons-180700285.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T18:07:00+00:00", "published_display": "22 Jun 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx and ASTS fund $100,000 study on kidney transplant testing costs", "summary": "Insight Molecular Diagnostics (iMDx) and the American Society of Transplant Surgeons (ASTS) have awarded a $100,000 research grant to Drs. Kenneth Andreoni and Kenneth Chavin. Their study will compare the health economics of in-house versus send-out donor-derived cell-free DNA (d", "url": "https://www.stocktitan.net/news/IMDX/i-m-dx-and-the-american-society-of-transplant-surgeons-announce-nr3q7tj2d4uj.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:41:44", "published_display": "22 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx and the American Society of Transplant Surgeons", "summary": "Insight Molecular Diagnostics Inc. (iMDx) and the American Society of Transplant Surgeons (ASTS) announced Dr. Kenneth Andreoni and Dr. Kenneth Chavin as recipients of a $100,000 grant. This grant supports research into the health economics of in-house versus send-out donor-deriv", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315564/0/en/imdx-and-the-american-society-of-transplant-surgeons-announce-recipients-of-the-asts-imdx-health-economics-research-grant.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T14:07:00", "published_display": "22 Jun 2026 14:07", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics and ASTS Award Grant for Health Economics Study of In-House vs. Send-Out dd-cfDNA Testing in Kidney Transplantation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxOdXlYUzZ5YkdzSUY3YU1rRzFxaU43amloWlFJQVQySE9oWmhiS1dIci02VjJOdThXZzdpUFVubDlLTF9ETTJaM0ZZUGFGNHlIWDFfYXU0d2pNa1JwdVU1U2JoNjEyR3ZCRlczVUdSWkV5RUVXUEVqQzhIUU5tNlJ2M2g1aXRTbHoyYkp2alFvdEZWNXh6ZGEzdXp0WF9RVzJRLVhYeHZ4Q0dUMHVrMlQzcWRjYzJ2cWdFeS1ScEJWai1BUUgtX19Sa2k0ODhIa29sZ01MQml0VjF4RTVQVWpQRU5WLVVHbVdwZFRYVGNRZHVsMm5ER2M0SWEtbnBZZ0FraG9CRHg1ZVBSdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Insight Molecular Diagnostics Ord Shs (IMDX), including future EPS and revenue growth estimates. Based on 4 analysts, the current rating is a \"Buy\" with a target price upside of 53.19%. The company's expected revenue for the next qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imdx/earnings", "source_name": "TradingKey", "published_at": "2026-06-22T06:40:25", "published_display": "22 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u200bBreakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)\u2019s Defining Moment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/breakthrough-science-meets-market-skepticism-181714816.html", "source_name": "Insider Monkey", "published_at": "2026-06-19T18:17:14+00:00", "published_display": "19 Jun 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)\u2019s Defining Moment", "summary": "Insight Molecular Diagnostics Inc. (IMDX) recently announced publication of new data for its GraftAssure transplant rejection monitoring assay, demonstrating its statistical superiority and correlation with kidney transplant rejection. This development comes as BTIG maintains a N", "url": "https://www.insidermonkey.com/blog/%E2%80%8Bbreakthrough-science-meets-market-skepticism-insight-molecular-diagnostics-inc-imdxs-defining-moment-1784827/", "source_name": "Insider Monkey", "published_at": "2026-06-19T18:40:02", "published_display": "19 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quest Diagnostics Stock - Analyst targets, sector review and weekly recap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxONXVEeDZuTjZDaXh0dnlqY0NPTENZX0c4cFBxSDV3UWh1NC1XMU9ialR4Wk5TbnlpRVpXU05EVENEYjAtcGpoZmR2TVhLandUM0tIS2V4Rmk0dDZJMk44bm9tbl9SRUwtcGNLOXBGOGp4WlNpeE1aY0ZwRDdEZzB2NDhhUXFCV0p1MFB2djBnaDdfREtqMmhHcTFFMHIwcy1qOURxR2c2QTQzTkNsczZqbklmb0h2WlE5OE51cUlZU0VyY2ZMeUpHVw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-19T16:09:41+00:00", "published_display": "19 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 High-Growth Micro-Cap Stocks to Buy Now", "summary": "This article lists high-growth micro-cap stocks, focusing on Insight Molecular Diagnostics Inc. (IMDX) as one such opportunity. It highlights IMDX's GraftAssure transplant rejection monitoring assay, its statistical superiority, and upcoming discussions at the American Transplant", "url": "https://www.insidermonkey.com/blog/12-high-growth-micro-cap-stocks-to-buy-now-1784069/2", "source_name": "Insider Monkey", "published_at": "2026-06-18T12:14:44", "published_display": "18 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX SEC Filings - Insight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Insight Molecular Diagnostics Inc. (IMDX) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents. It highlights recent filings detailing a significant option grant to CEO Josh Riggs and salary increases for the CEO and CFO. The", "url": "https://www.stocktitan.net/sec-filings/IMDX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-18T01:09:32", "published_display": "18 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase", "summary": "Insight Molecular Diagnostics Inc. (IMDX) shareholders approved all proposals at their 2026 annual meeting, including the election of four directors, the ratification of CBIZ CPAs P.C. as the accounting firm, and the approval of executive officer compensation on an advisory basis", "url": "https://www.stocktitan.net/sec-filings/IMDX/8-k-insight-molecular-diagnostics-inc-reports-material-event-c4335e1f1d0e.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:09:32", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Favorable Head-to-Head Data on iMDx\u2019s GraftAssure with Competing NGS Assay Published in Clinical Chemistry", "summary": "Insight Molecular Diagnostics Inc. (iMDx) announced the publication of a study in Clinical Chemistry demonstrating high concordance between its GraftAssure\u2122 transplant monitoring test and a leading NGS-based assay. GraftAssure\u2122 showed 99.2% agreement and improved analytical sensi", "url": "https://www.sahmcapital.com/news/content/favorable-head-to-head-data-on-imdxs-graftassure-with-competing-ngs-assay-published-in-clinical-chemistry-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-16T21:09:33", "published_display": "16 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New lab test rivals DNA sequencing to monitor kidney transplants", "summary": "Insight Molecular Diagnostics (IMDX) announced positive head-to-head data for its GraftAssure transplant monitoring test, published in Clinical Chemistry. The study showed 99.2% agreement with a leading next-generation sequencing (NGS) assay for kidney rejection risk assessment, ", "url": "https://www.stocktitan.net/news/IMDX/favorable-head-to-head-data-on-i-m-dx-s-graft-assure-with-competing-zcthbqbfz9ql.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:39:53", "published_display": "16 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity", "summary": "Insight Molecular Diagnostics Inc. (IMDX) director Andrew J. Last reported receiving 26,943 Restricted Stock Units (RSUs) at a price of $0.00, increasing his direct holdings to 66,452 shares. These RSUs will vest at the next annual shareholders' meeting, contingent on his continu", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-23d693564386.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:09:46", "published_display": "15 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/imdx-graftassure-assay-sets-standard-201700927.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T20:17:00+00:00", "published_display": "11 Jun 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxNQTBGT2Rsc2pSTnVRQVlteThHcEwtb0ZUcWhodjRKcm9pU2tFQmVFdHcyc0ZyeEs2S1Y0bVBBLXFjcHpTVWVEbERoVHNLa1dxaVlnbUJpTUF4SU9Jdk1vRnRVYzEtYjZIOFBsV2otUDdETk1YaV8ta0NyVVY0dGZ5UTA0aGlNMHZuRWtjZHdCMGZ6YkNlY0o0RlRKRnBBdmQzMnF5NjRvalM1MVIzemFtRnAwOHNwaHlEVkdDRDlOeW9EOGRsY0dSV3kzUWRjbHlaeW5WejBwMjlxd2hFcWNUWUV5LVcwZ3dGR0FtRDQxLS0zVnhiTjdKcTAzbFE1c21Tb2R0X1F0S0FNckZZRU15Zg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/imdx-highlight-house-transplant-testing-200500649.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T20:05:00+00:00", "published_display": "09 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdkI5WlpaY1hEX3lxTUlPMTNOMkhkeWlySFYwcVNJcnVrb2dCYTR5dVVYOXhncm9VQWNTcW1OdklucHljM2pvYWNkQnNuMGVtQmtUdTdfMEFvVHdrM19fVjdIbmVKb2ZIaEMxUlBDcS1wVWlxSDJMeDlyNk5RRmhwNjNBcW55eVFNNUpyNnJoQkxzUmZOclhXX2szY3lvWHVpU2Q3bWtfV2k?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/insight-molecular-diagnostics-inc-imdx-050056604.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T05:00:56+00:00", "published_display": "14 May 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/insight-molecular-diagnostics-q1-earnings-201737426.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:17:37+00:00", "published_display": "13 May 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPR2dDX0JwTGZIVUZjMHFxRmVrOHNSYVdBRHBhVFEtMHBvaEZaQzRfZUxMeDhfMDlnM3ZybTZabFkyX0dmWGxYMGItaFNvOXgzRm4zX3NqTmlRTFJ0WFFKc0VZOUxSMl9WbEhjdDhjdVlWWnNoUjBINEgxbDNaZDIxMDhaX3dtc2oyNWY5YWU2bWpMYlZKT0FPQTRFSnN5UnNvYXlyZk05TWxxejRaVHc?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxONGxDeXZJNV9YdWZvYi1KSkdCTWpZRm4zN2syYjVYZVBhbU9UY0stUXVzMm9EVjh6dWF0TzQzbG9CUmRidXRBeUtPaHRMR1lFVFMwM0RIclZ3UEdjNFY1VnpMaThTZC12OUx6bjJHMDVNRVpMV1FNZnVYaFdoY0RzenlhWTR3UTRtVGM2SWlFRy1vbGxpVHE4anl0bVF1YmNqanh5QUlRSnZ4akk?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPME5qUTVBSUJJeUVsSkl0M0Q0V2RkalAzN25zZHBqTHZXbFd6NHNoa3dLT01pRjByaExaTnpvbDZuY3BEU05QWHgwNVE3bW4yTlNEazU3eXloYmRUUGJWME1nOTM4X0pUMGs4YXFyRVF0WGdsSmwtSkxXcmcwYlhSSlNpWEgtaElTTG9kQWZPV3g4cmM?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX | Insight Molecular Diagnostics Inc. Institutional Ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTFBoWC1ldEM2dFFGVEUzUDU4dGEtdmxmdmxNT0lRYjl1V1hsdkdLT0RfemlPNmNfU0MtTVdkNWRXMi1RVS1ULTZ0cDBlQ0lVWmJJY1VPV2lLTGwwRzgwaFJtSFN3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-29T04:18:57+00:00", "published_display": "29 Jul 2025 04:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOUndXdHhISXpPeUl3M3ItLTliTXhTM1FydkNHV0lMZXZoNUM3dTRDTXhHSWVKRHhlbXdUd2x6RXlWU1pOTGlOWi00N3J5THl5VUhkQWdEQjRPaWZ0Y0dvY1FtcFJLWURUbEtGSFMzUXBueVRlNURPcFlBTlpUTXQ3Y0Z3YnhvZUprYUJQdVZR?oc=5", "source_name": "Market source", "published_at": "2025-06-17T07:00:00+00:00", "published_display": "17 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNUUpkR2h0T0JuSHFUUDc0M0doWDd6bmpVOFFGMk5jaGlNY2hGcGo1VDVvbTRueG4xUkpWUE1LREhqSHg0dzRhZGktZExmeHgzdUFnUUlwdU9waVRkUEs3QU1EQW9jcUdLNHBNZzBnUVN6cFotb3FMeUFaSEs5VmExeWZFLWtpbVh1MTZIdGhNdWlfenhhbXBwNEllWlhkZ05OWlRLVUVQR1B5bnZLdmI2aTZlUXl4Q2ZfczRnVzZ1TllXeUlrN0ZJbEZHaw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T05:17:08+00:00", "published_display": "21 Jul 2026 05:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen stock trades steady as investors weigh recent earnings and diagnostics demand", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOY2lWQW5SZGVnT0ZmTkxpMTJ1YUx2ai1jYWFiWkRrZzBXZ056bzBnQzhjczF1OXp4YjM0cGJjNGxweDJsXzA0OFpBbGRHd3hHeU1NdlRUcTUycWI3WlVpZ3JZMk1yeGlFTnpwQnRZSHR3MGNKQ25yRkF0Zy1CYS0zRmJrbnM4UHJKMHREWV9QZU04Slh1eHItME5vRW1EaTctN3d4bHJiYjFyOENwWTY1QXlZT292cnV3cmdiMnJUM1lSdw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T11:16:28+00:00", "published_display": "20 Jul 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEXX Laboratories stock stays anchored to its diagnostics growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQTGtXazQ2emZha2llSjlaYldkV01VdWhuc3htd1BRQ3B2OVNQTzJxTEktT2hKdFdMNDhxRWVlV0ZkY0dmRHhHOFh0X0xXOU9WcGx5UEFRS2JGLUtHTWluOXVWSEplLUpTOC1zQzlNWDNpcEVUdnA4ZDFlbU1UTC03cHVQdDg2cHlteFE4RmxKc3A2MHhldzNZVHF6ZlJxOTUtNklORkYtRURkT1dPTTM3UHdzMXhuSTV5aGIyTW81WmpUZw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T10:50:44+00:00", "published_display": "20 Jul 2026 10:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its enterprise value to revenue forward. The content, sourced from TradingView, indicates a market closed status with no trades and highlights financial dat", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T06:40:16", "published_display": "20 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen stock trades steady as diagnostics demand supports earnings and cash flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQeEE2NXcxNFlzM2VhVkZjX3lMajV3QzNVd1V2d3dXMllRUzVNa2RHbzVhcEZueEpnZFpyYXNKOU9ZZzdtOXdzMVZoRUV0bEd1MVFJYkJKSzAzSjdaajdVUi1TR1RfZmJrNDIydWI2R2dlRU1jdmU5NmV6dDNwZ3pWdG1BRTNHZjVabTdtUzNpckNCX2V5VVIteVkwVzZfMmJNVlNTZy1Tb2t2M0dEZDM3TmoxaGlkZ2lvX1RQWWZZYk9PVjJMNXFzSQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-19T01:57:24+00:00", "published_display": "19 Jul 2026 01:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medicare expands coverage for transplant monitoring test, boosting Insight Molecular Diagnostics' GraftAssure adoption.", "summary": "Medicare has expanded its coverage for donor-derived cell-free DNA (dd-cfDNA) testing, which will increase patient access and testing frequency for kidney and heart transplant recipients. This policy change will benefit Insight Molecular Diagnostics (iMDx) and its GraftAssure tra", "url": "https://pluang.com/en/news-feed/keputusan-medicare-mendukung-adopsi-komersial-portofolio-graftassure-imdx", "source_name": "Pluang", "published_at": "2026-07-16T20:11:30", "published_display": "16 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing", "summary": "Insight Molecular Diagnostics Inc. (iMDx) announced that Medicare has expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care, a move expected to boost the commercial adoption of its GraftAssure\u2122 assays. The new MolDX policy clarifies reimbursement", "url": "https://www.quiverquant.com/news/iMDx+Highlights+Expanded+Medicare+Coverage+for+Donor-Derived+Cell-Free+DNA+Transplant+Testing", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T19:30:00", "published_display": "16 Jul 2026 19:30", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio", "summary": "Insight Molecular Diagnostics Inc. (iMDx) has announced a favorable new Medicare policy that significantly expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. This policy clarifies reimbursement guidelines, increases testing frequencies for tra", "url": "https://www.globenewswire.com/fr/news-release/2026/07/16/3328769/0/en/favorable-medicare-coverage-decision-supports-commercial-adoption-of-imdx-graftassure-assay-portfolio.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T15:22:00", "published_display": "16 Jul 2026 15:22", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its \"Price to book forward\" metric. It appears to be an entry from a financial data platform, giving a snapshot of the company's valuation for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T10:10:28", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen stock holds steady as diagnostics demand supports long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQYXRxTGlQaFZybjJ5a2J0WHl5bXp5QTRPMS1vTG5XVUoyU3Z4ZlRiSnUtRTQ2TWF4dG9FSzkwYmRYcnhDZUFqXzVuSTdFVEg1eVU0TXBNS2k0V2xEdm9MR3lzNTlCMzN3UEpMNmppZTlfbEZRWGloRm84VjllY0dtTUNMM3pCZFdyVUlPaS1saXdOOU1OVzVDa29zRURQZXlsRVZ6M3pITWVVSmVyQXZpSXIwWGxyaWxQZ1VNRTgwRGo4RndMZEE2MERVZlQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-13T06:08:44+00:00", "published_display": "13 Jul 2026 06:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "The article provides a financial statistic, specifically the Enterprise Value to EBIT (Earnings Before Interest and Taxes) forward for Insight Molecular Diagnostics Inc. (NASDAQ:IMDX). It appears to be a stub or a data point from a financial platform like TradingView, indicating ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T07:39:55", "published_display": "12 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roche stock holds steady as pharma giant leans on diagnostics and oncology strength", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPa0hsdjNPUWxBTFVtcXYyOUpSbnB0WnpoR1k5c1EyaFVPOXJmR0NROGpoazIwMC1FWFFiYmh4VGl5ZkZHbEFtNXNBalBIbTY5Q29aSXdNTkpiNEU4ZDdIZHJ2SjNoYjRqaHBLdUNSYTBieUhEdHBzc1V0UFQ3QkxPZ0s0d2pSWWhid3pOQW5uMUVHRmRpQmpCa0FkY2hrVHM4c2ViTFRWOWpLVkY2NWpBM0FuMkFDZWlUaG5ncWl4ckxNeENDMjhHWVpUSG8xUQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-11T08:31:21+00:00", "published_display": "11 Jul 2026 08:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Insight Molecular Diagnostics Inc. \u2013 NASDAQ:IMDX", "summary": "This article provides a specific financial metric, \"Price to sales forward,\" for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX). The content is primarily a listing from TradingView, highlighting the company's stock information, along with various platform features and disclaim", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T12:40:45", "published_display": "10 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Insight Molecular Diagnostics Inc For: 6 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Molecular Diagnostics Inc. on July 6th, 2026. The filing indicates insider transaction activity for the company, which is trading down 12.59% (IMDX). The article provides no further details on the nature of the Form 4", "url": "https://ng.investing.com/news/stock-market-news/form-4-insight-molecular-diagnostics-inc-for-6-july-93CH-2587994", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T04:39:14", "published_display": "07 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Lou Silverman has IMDX shares withheld for taxes (NASDAQ: IMDX)", "summary": "Insight Molecular Diagnostics Inc. director Lou Silverman reported that 7,700 shares of common stock, valued at $5.69 per share, were withheld to cover tax obligations arising from the vesting of 35,000 restricted stock units. This was not a market sale, but a routine tax-related", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-0d03de98f339.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:06", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular (IMDX) director uses 12,100 shares to cover RSU tax withholding", "summary": "Insight Molecular Diagnostics Inc. director Arno Andrew reported that 12,100 shares of Common Stock, valued at $5.69 per share, were withheld by the company to cover tax obligations related to the vesting of 55,000 restricted stock units. Critically, Andrew did not sell any share", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-f85382365a76.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:06", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics (Nasdaq: IMDX) details director RSU tax withholding", "summary": "Insight Molecular Diagnostics director Andrew J. Last reported a tax-withholding transaction related to vested restricted stock units (RSUs). For tax obligations on 35,000 RSUs, 7,700 shares of common stock were withheld at $5.69 per share. This was not an open-market sale, and L", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-410314e347ba.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:06", "published_display": "07 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quest Diagnostics (DGX) Stock Analysis: Revenue Growth and Dividend Yield Capture Investor Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNYkVVSF9CRDFhU0s1LVZ0V0diSmdaUjB4bGd0Y0V1d2tlVVdLY2FCNjdmODBvQjBCaDRoazNuQ2RQTmtBcUFTeHdXckpzNWwwbnNpS1F1YUdqSld1Y3Rkay1SaHNPdDh5RHpQV1pyVHBsMHh1ZG5iOUo5eUE4QnE4TTFrQ1JOaXQ5RmduVVF4d3dtZWE0WExvRy1JdU95RmZocjMwUElOZUUzcHI2RlRVNmZEYklLR1o4a2lONDFBRDlucUNXQk1fQ3JuSnRxS2k5QkJOR3psNlFFWUhOUGszZ2Zn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:16:18+00:00", "published_display": "06 Jul 2026 09:16", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Insight Molecular Diagnostics Inc. (IMDX)", "summary": "This article examines the hypothetical return on a $1,000 investment in Insight Molecular Diagnostics Inc. (IMDX). It shows that an investment made one year ago would now be worth $1,694, representing a 69.4% total return. The piece also provides a detailed overview of the compan", "url": "https://www.stocktitan.net/tools/stock-return-calculator/IMDX", "source_name": "Stock Titan", "published_at": "2026-07-06T04:39:14", "published_display": "06 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX - Insight Molecular Diagnostics Inc Website Traffic and Mobile Apps Usage", "summary": "This article provides a detailed financial overview of Insight Molecular Diagnostics Inc. (IMDX), including stock performance, key financial metrics, recent news, and insider trading activity. It highlights the company's focus on diagnostic tests for cancer and transplant monitor", "url": "https://finviz.com/stock?t=IMDX&ty=tr", "source_name": "Finviz", "published_at": "2026-07-04T11:09:14", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics (Nasdaq:IMDX) - Stock Analysis", "summary": "Insight Molecular Diagnostics (IMDX) operates as a precision diagnostics company with a market cap of US$183.7 million. While the company faces risks such as a highly volatile share price, negative shareholder equity, unprofitability, and minimal revenue, it anticipates significa", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics", "source_name": "Simply Wall Street", "published_at": "2026-07-01T14:39:44", "published_display": "01 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper", "summary": "Insight Molecular Diagnostics Inc. (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. Dr. Schuetz is a co-inventor of the dd-cfDNA testing technology used in iMDx\u2019s GraftAssure assays and is recognized as a top", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318899/0/en/imdx-chief-science-officer-ekkehard-schuetz-publishes-200th-research-paper.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:09:33", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx science chief hits 200 papers as transplant test work builds", "summary": "Insight Molecular Diagnostics (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. Dr. Schuetz co-invented the dd-cfDNA technology central to iMDx's GraftAssure assays, which are designed for transplant rejection", "url": "https://www.stocktitan.net/news/IMDX/im-dx-chief-science-officer-ekkehard-schuetz-publishes-200th-kd8kokxwmwnt.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:09:33", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc. Actuals & Estimates (NASDAQ:IMDX)", "summary": "This article provides an overview of Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), detailing its current stock price, historical performance, and analyst forecasts. It includes key financial data like market capitalization, earnings per share, and revenue, along with employe", "url": "https://www.tradingview.com/symbols/NASDAQ-IMDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T13:13:12", "published_display": "27 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX)", "summary": "This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It covers stock performance, earnings reports, revenue, net income, and EBITDA, along with freque", "url": "https://www.tradingview.com/symbols/BOATS-IMDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:39:18", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Qiagen N.V. updates earnings calendar, shares tracked against diagnostics peers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOUTNqbEpUTW4xd3RUTE5nMEt0ZEJFT25xZVBoYjRYYk56b18xdkwyWFJncVR1cjMwa25pbUhudWk2Ukk5RlBqLU1fRXo5YmZXNlZQMG5ubnExM1o4YXZpSDE3enY4T0MtLTVIS1dnYUlVWTZMNW5HVkFKNVFFbFZRVnQ3Z0ZkNnJmN0NMRHVRZXJtQkw2b1RUazZSZW1yaTVCM0VVYU9RM1o3YWF4MHlZM2ppSWZnekVxUEN4Y01GaWRiUXVTMHE0bXRB?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T05:11:57+00:00", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing", "summary": "Insight Molecular Diagnostics (IMDX) is poised for a significant repricing due to its GraftAssure transplant monitoring test. Recent Clinical Chemistry and American Journal of Transplantation articles highlight its high concordance, diagnostic performance, and potential for earli", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics/stf1tyro-rising-global-organ-transplants-will-drive-diagnostic-testing-expansion-55ap/updates/20-analysts-have-adjusted-their-price-target-for-insight-molecu", "source_name": "Simply Wall Street", "published_at": "2026-06-25T02:09:49", "published_display": "25 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imdx-american-society-transplant-surgeons-180700285.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T18:07:00+00:00", "published_display": "22 Jun 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx and ASTS fund $100,000 study on kidney transplant testing costs", "summary": "Insight Molecular Diagnostics (iMDx) and the American Society of Transplant Surgeons (ASTS) have awarded a $100,000 research grant to Drs. Kenneth Andreoni and Kenneth Chavin. Their study will compare the health economics of in-house versus send-out donor-derived cell-free DNA (d", "url": "https://www.stocktitan.net/news/IMDX/i-m-dx-and-the-american-society-of-transplant-surgeons-announce-nr3q7tj2d4uj.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:41:44", "published_display": "22 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx and the American Society of Transplant Surgeons", "summary": "Insight Molecular Diagnostics Inc. (iMDx) and the American Society of Transplant Surgeons (ASTS) announced Dr. Kenneth Andreoni and Dr. Kenneth Chavin as recipients of a $100,000 grant. This grant supports research into the health economics of in-house versus send-out donor-deriv", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315564/0/en/imdx-and-the-american-society-of-transplant-surgeons-announce-recipients-of-the-asts-imdx-health-economics-research-grant.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T14:07:00", "published_display": "22 Jun 2026 14:07", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics and ASTS Award Grant for Health Economics Study of In-House vs. Send-Out dd-cfDNA Testing in Kidney Transplantation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxOdXlYUzZ5YkdzSUY3YU1rRzFxaU43amloWlFJQVQySE9oWmhiS1dIci02VjJOdThXZzdpUFVubDlLTF9ETTJaM0ZZUGFGNHlIWDFfYXU0d2pNa1JwdVU1U2JoNjEyR3ZCRlczVUdSWkV5RUVXUEVqQzhIUU5tNlJ2M2g1aXRTbHoyYkp2alFvdEZWNXh6ZGEzdXp0WF9RVzJRLVhYeHZ4Q0dUMHVrMlQzcWRjYzJ2cWdFeS1ScEJWai1BUUgtX19Sa2k0ODhIa29sZ01MQml0VjF4RTVQVWpQRU5WLVVHbVdwZFRYVGNRZHVsMm5ER2M0SWEtbnBZZ0FraG9CRHg1ZVBSdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Insight Molecular Diagnostics Ord Shs (IMDX), including future EPS and revenue growth estimates. Based on 4 analysts, the current rating is a \"Buy\" with a target price upside of 53.19%. The company's expected revenue for the next qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imdx/earnings", "source_name": "TradingKey", "published_at": "2026-06-22T06:40:25", "published_display": "22 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u200bBreakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)\u2019s Defining Moment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/breakthrough-science-meets-market-skepticism-181714816.html", "source_name": "Insider Monkey", "published_at": "2026-06-19T18:17:14+00:00", "published_display": "19 Jun 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)\u2019s Defining Moment", "summary": "Insight Molecular Diagnostics Inc. (IMDX) recently announced publication of new data for its GraftAssure transplant rejection monitoring assay, demonstrating its statistical superiority and correlation with kidney transplant rejection. This development comes as BTIG maintains a N", "url": "https://www.insidermonkey.com/blog/%E2%80%8Bbreakthrough-science-meets-market-skepticism-insight-molecular-diagnostics-inc-imdxs-defining-moment-1784827/", "source_name": "Insider Monkey", "published_at": "2026-06-19T18:40:02", "published_display": "19 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quest Diagnostics Stock - Analyst targets, sector review and weekly recap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxONXVEeDZuTjZDaXh0dnlqY0NPTENZX0c4cFBxSDV3UWh1NC1XMU9ialR4Wk5TbnlpRVpXU05EVENEYjAtcGpoZmR2TVhLandUM0tIS2V4Rmk0dDZJMk44bm9tbl9SRUwtcGNLOXBGOGp4WlNpeE1aY0ZwRDdEZzB2NDhhUXFCV0p1MFB2djBnaDdfREtqMmhHcTFFMHIwcy1qOURxR2c2QTQzTkNsczZqbklmb0h2WlE5OE51cUlZU0VyY2ZMeUpHVw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-19T16:09:41+00:00", "published_display": "19 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 High-Growth Micro-Cap Stocks to Buy Now", "summary": "This article lists high-growth micro-cap stocks, focusing on Insight Molecular Diagnostics Inc. (IMDX) as one such opportunity. It highlights IMDX's GraftAssure transplant rejection monitoring assay, its statistical superiority, and upcoming discussions at the American Transplant", "url": "https://www.insidermonkey.com/blog/12-high-growth-micro-cap-stocks-to-buy-now-1784069/2", "source_name": "Insider Monkey", "published_at": "2026-06-18T12:14:44", "published_display": "18 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX SEC Filings - Insight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Insight Molecular Diagnostics Inc. (IMDX) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents. It highlights recent filings detailing a significant option grant to CEO Josh Riggs and salary increases for the CEO and CFO. The", "url": "https://www.stocktitan.net/sec-filings/IMDX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-18T01:09:32", "published_display": "18 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase", "summary": "Insight Molecular Diagnostics Inc. (IMDX) shareholders approved all proposals at their 2026 annual meeting, including the election of four directors, the ratification of CBIZ CPAs P.C. as the accounting firm, and the approval of executive officer compensation on an advisory basis", "url": "https://www.stocktitan.net/sec-filings/IMDX/8-k-insight-molecular-diagnostics-inc-reports-material-event-c4335e1f1d0e.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:09:32", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Favorable Head-to-Head Data on iMDx\u2019s GraftAssure with Competing NGS Assay Published in Clinical Chemistry", "summary": "Insight Molecular Diagnostics Inc. (iMDx) announced the publication of a study in Clinical Chemistry demonstrating high concordance between its GraftAssure\u2122 transplant monitoring test and a leading NGS-based assay. GraftAssure\u2122 showed 99.2% agreement and improved analytical sensi", "url": "https://www.sahmcapital.com/news/content/favorable-head-to-head-data-on-imdxs-graftassure-with-competing-ngs-assay-published-in-clinical-chemistry-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-16T21:09:33", "published_display": "16 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New lab test rivals DNA sequencing to monitor kidney transplants", "summary": "Insight Molecular Diagnostics (IMDX) announced positive head-to-head data for its GraftAssure transplant monitoring test, published in Clinical Chemistry. The study showed 99.2% agreement with a leading next-generation sequencing (NGS) assay for kidney rejection risk assessment, ", "url": "https://www.stocktitan.net/news/IMDX/favorable-head-to-head-data-on-i-m-dx-s-graft-assure-with-competing-zcthbqbfz9ql.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:39:53", "published_display": "16 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity", "summary": "Insight Molecular Diagnostics Inc. (IMDX) director Andrew J. Last reported receiving 26,943 Restricted Stock Units (RSUs) at a price of $0.00, increasing his direct holdings to 66,452 shares. These RSUs will vest at the next annual shareholders' meeting, contingent on his continu", "url": "https://www.stocktitan.net/sec-filings/IMDX/form-4-insight-molecular-diagnostics-inc-insider-trading-activity-23d693564386.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:09:46", "published_display": "15 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/imdx-graftassure-assay-sets-standard-201700927.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T20:17:00+00:00", "published_display": "11 Jun 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxNQTBGT2Rsc2pSTnVRQVlteThHcEwtb0ZUcWhodjRKcm9pU2tFQmVFdHcyc0ZyeEs2S1Y0bVBBLXFjcHpTVWVEbERoVHNLa1dxaVlnbUJpTUF4SU9Jdk1vRnRVYzEtYjZIOFBsV2otUDdETk1YaV8ta0NyVVY0dGZ5UTA0aGlNMHZuRWtjZHdCMGZ6YkNlY0o0RlRKRnBBdmQzMnF5NjRvalM1MVIzemFtRnAwOHNwaHlEVkdDRDlOeW9EOGRsY0dSV3kzUWRjbHlaeW5WejBwMjlxd2hFcWNUWUV5LVcwZ3dGR0FtRDQxLS0zVnhiTjdKcTAzbFE1c21Tb2R0X1F0S0FNckZZRU15Zg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/imdx-highlight-house-transplant-testing-200500649.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T20:05:00+00:00", "published_display": "09 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdkI5WlpaY1hEX3lxTUlPMTNOMkhkeWlySFYwcVNJcnVrb2dCYTR5dVVYOXhncm9VQWNTcW1OdklucHljM2pvYWNkQnNuMGVtQmtUdTdfMEFvVHdrM19fVjdIbmVKb2ZIaEMxUlBDcS1wVWlxSDJMeDlyNk5RRmhwNjNBcW55eVFNNUpyNnJoQkxzUmZOclhXX2szY3lvWHVpU2Q3bWtfV2k?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/insight-molecular-diagnostics-inc-imdx-050056604.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T05:00:56+00:00", "published_display": "14 May 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insight Molecular Diagnostics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/insight-molecular-diagnostics-q1-earnings-201737426.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:17:37+00:00", "published_display": "13 May 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPR2dDX0JwTGZIVUZjMHFxRmVrOHNSYVdBRHBhVFEtMHBvaEZaQzRfZUxMeDhfMDlnM3ZybTZabFkyX0dmWGxYMGItaFNvOXgzRm4zX3NqTmlRTFJ0WFFKc0VZOUxSMl9WbEhjdDhjdVlWWnNoUjBINEgxbDNaZDIxMDhaX3dtc2oyNWY5YWU2bWpMYlZKT0FPQTRFSnN5UnNvYXlyZk05TWxxejRaVHc?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxONGxDeXZJNV9YdWZvYi1KSkdCTWpZRm4zN2syYjVYZVBhbU9UY0stUXVzMm9EVjh6dWF0TzQzbG9CUmRidXRBeUtPaHRMR1lFVFMwM0RIclZ3UEdjNFY1VnpMaThTZC12OUx6bjJHMDVNRVpMV1FNZnVYaFdoY0RzenlhWTR3UTRtVGM2SWlFRy1vbGxpVHE4anl0bVF1YmNqanh5QUlRSnZ4akk?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPME5qUTVBSUJJeUVsSkl0M0Q0V2RkalAzN25zZHBqTHZXbFd6NHNoa3dLT01pRjByaExaTnpvbDZuY3BEU05QWHgwNVE3bW4yTlNEazU3eXloYmRUUGJWME1nOTM4X0pUMGs4YXFyRVF0WGdsSmwtSkxXcmcwYlhSSlNpWEgtaElTTG9kQWZPV3g4cmM?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMDX | Insight Molecular Diagnostics Inc. Institutional Ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTFBoWC1ldEM2dFFGVEUzUDU4dGEtdmxmdmxNT0lRYjl1V1hsdkdLT0RfemlPNmNfU0MtTVdkNWRXMi1RVS1ULTZ0cDBlQ0lVWmJJY1VPV2lLTGwwRzgwaFJtSFN3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-29T04:18:57+00:00", "published_display": "29 Jul 2025 04:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOUndXdHhISXpPeUl3M3ItLTliTXhTM1FydkNHV0lMZXZoNUM3dTRDTXhHSWVKRHhlbXdUd2x6RXlWU1pOTGlOWi00N3J5THl5VUhkQWdEQjRPaWZ0Y0dvY1FtcFJLWURUbEtGSFMzUXBueVRlNURPcFlBTlpUTXQ3Y0Z3YnhvZUprYUJQdVZR?oc=5", "source_name": "Market source", "published_at": "2025-06-17T07:00:00+00:00", "published_display": "17 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 93, "total_relevant": 53, "sentiment_summary": {"positive": 18, "negative": 1, "neutral": 34, "score": 58, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 7.5, "count": 13}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 4.74, "latest_week": "2026-07-17", "one_week_move": -6.7, "four_week_move": -12.9, "twelve_week_move": 26.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.289817, "market_dynamics_buy_signal": false, "relative_strength": -13.38404, "fair_value_gap": 30.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 45.0169, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.7% over one week, -12.9% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Ad-hoc-news.de", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "GlobeNewswire", "count": 6}, {"label": "Quiver Quantitative", "count": 4}, {"label": "Market source", "count": 4}, {"label": "Insider Monkey", "count": 3}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 13}, {"label": "Macro sensitivity", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.7% over one week, -12.9% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow"}], "updated_at": "2026-07-21T18:24:06.625955+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}